LOGIN
Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma
June 2022
Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial
Adv Clin Exp Med. 2022 01-Mar;():. 10.17219/acem/142332Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
200 pediatric osteosarcoma patients were randomized to receive a single intravenous dose of palonosetron or granisetron for antiemetic prophylaxis. The primary outcome was patient response to treatment in the first 24 hours after chemotherapy (complete response; partial response; failure). Adverse events were also recorded. Results found that patients who received palonosetron had a significantly ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.